Cargando…
PB1889: KB-LANRA 1001: A PHASE 1B/2 STUDY ON SAFETY, PK, PD, AND PRELIMINARY EFFICACY OF THE SELECTIVE SYK INHIBITOR LANRAPLENIB IN COMBINATION WITH THE FLT3 INHIBITOR GILTERITINIB, IN FLT3-MUTATED R/R AML
| Autores principales: | , , , , , , , , , , |
|---|---|
| Formato: | Online Artículo Texto |
| Lenguaje: | English |
| Publicado: |
Lippincott Williams & Wilkins
2023
|
| Materias: | |
| Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10429830/ http://dx.doi.org/10.1097/01.HS9.0000974380.14929.94 |
| _version_ | 1785090809757958144 |
|---|---|
| author | Patel, Anand Michaelis, Laura Schiller, Gary Swords, Ronan Morris, Lawrence E. Carvajal, Luis A. Bray, Gordon Olek, Elizabeth A. Cutler, Richard Dimartino, Jorge Stein, Eytan |
| author_facet | Patel, Anand Michaelis, Laura Schiller, Gary Swords, Ronan Morris, Lawrence E. Carvajal, Luis A. Bray, Gordon Olek, Elizabeth A. Cutler, Richard Dimartino, Jorge Stein, Eytan |
| author_sort | Patel, Anand |
| collection | PubMed |
| description | |
| format | Online Article Text |
| id | pubmed-10429830 |
| institution | National Center for Biotechnology Information |
| language | English |
| publishDate | 2023 |
| publisher | Lippincott Williams & Wilkins |
| record_format | MEDLINE/PubMed |
| spelling | pubmed-104298302023-08-17 PB1889: KB-LANRA 1001: A PHASE 1B/2 STUDY ON SAFETY, PK, PD, AND PRELIMINARY EFFICACY OF THE SELECTIVE SYK INHIBITOR LANRAPLENIB IN COMBINATION WITH THE FLT3 INHIBITOR GILTERITINIB, IN FLT3-MUTATED R/R AML Patel, Anand Michaelis, Laura Schiller, Gary Swords, Ronan Morris, Lawrence E. Carvajal, Luis A. Bray, Gordon Olek, Elizabeth A. Cutler, Richard Dimartino, Jorge Stein, Eytan Hemasphere Publication Only Lippincott Williams & Wilkins 2023-08-08 /pmc/articles/PMC10429830/ http://dx.doi.org/10.1097/01.HS9.0000974380.14929.94 Text en Copyright © 2023 The Author(s). Published by Wolters Kluwer Health, Inc. https://creativecommons.org/licenses/by-nc-nd/4.0/This is an open access Abstract Book distributed under the Attribution-NonCommercial-NoDerivs (CC BY-NC-ND) (https://creativecommons.org/licenses/by-nc-nd/4.0/) which allows third parties to download the articles and share them with others as long as they credit the author and the Abstract Book, but they cannot change the content in any way or use them commercially. |
| spellingShingle | Publication Only Patel, Anand Michaelis, Laura Schiller, Gary Swords, Ronan Morris, Lawrence E. Carvajal, Luis A. Bray, Gordon Olek, Elizabeth A. Cutler, Richard Dimartino, Jorge Stein, Eytan PB1889: KB-LANRA 1001: A PHASE 1B/2 STUDY ON SAFETY, PK, PD, AND PRELIMINARY EFFICACY OF THE SELECTIVE SYK INHIBITOR LANRAPLENIB IN COMBINATION WITH THE FLT3 INHIBITOR GILTERITINIB, IN FLT3-MUTATED R/R AML |
| title | PB1889: KB-LANRA 1001: A PHASE 1B/2 STUDY ON SAFETY, PK, PD, AND PRELIMINARY EFFICACY OF THE SELECTIVE SYK INHIBITOR LANRAPLENIB IN COMBINATION WITH THE FLT3 INHIBITOR GILTERITINIB, IN FLT3-MUTATED R/R AML |
| title_full | PB1889: KB-LANRA 1001: A PHASE 1B/2 STUDY ON SAFETY, PK, PD, AND PRELIMINARY EFFICACY OF THE SELECTIVE SYK INHIBITOR LANRAPLENIB IN COMBINATION WITH THE FLT3 INHIBITOR GILTERITINIB, IN FLT3-MUTATED R/R AML |
| title_fullStr | PB1889: KB-LANRA 1001: A PHASE 1B/2 STUDY ON SAFETY, PK, PD, AND PRELIMINARY EFFICACY OF THE SELECTIVE SYK INHIBITOR LANRAPLENIB IN COMBINATION WITH THE FLT3 INHIBITOR GILTERITINIB, IN FLT3-MUTATED R/R AML |
| title_full_unstemmed | PB1889: KB-LANRA 1001: A PHASE 1B/2 STUDY ON SAFETY, PK, PD, AND PRELIMINARY EFFICACY OF THE SELECTIVE SYK INHIBITOR LANRAPLENIB IN COMBINATION WITH THE FLT3 INHIBITOR GILTERITINIB, IN FLT3-MUTATED R/R AML |
| title_short | PB1889: KB-LANRA 1001: A PHASE 1B/2 STUDY ON SAFETY, PK, PD, AND PRELIMINARY EFFICACY OF THE SELECTIVE SYK INHIBITOR LANRAPLENIB IN COMBINATION WITH THE FLT3 INHIBITOR GILTERITINIB, IN FLT3-MUTATED R/R AML |
| title_sort | pb1889: kb-lanra 1001: a phase 1b/2 study on safety, pk, pd, and preliminary efficacy of the selective syk inhibitor lanraplenib in combination with the flt3 inhibitor gilteritinib, in flt3-mutated r/r aml |
| topic | Publication Only |
| url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10429830/ http://dx.doi.org/10.1097/01.HS9.0000974380.14929.94 |
| work_keys_str_mv | AT patelanand pb1889kblanra1001aphase1b2studyonsafetypkpdandpreliminaryefficacyoftheselectivesykinhibitorlanraplenibincombinationwiththeflt3inhibitorgilteritinibinflt3mutatedrraml AT michaelislaura pb1889kblanra1001aphase1b2studyonsafetypkpdandpreliminaryefficacyoftheselectivesykinhibitorlanraplenibincombinationwiththeflt3inhibitorgilteritinibinflt3mutatedrraml AT schillergary pb1889kblanra1001aphase1b2studyonsafetypkpdandpreliminaryefficacyoftheselectivesykinhibitorlanraplenibincombinationwiththeflt3inhibitorgilteritinibinflt3mutatedrraml AT swordsronan pb1889kblanra1001aphase1b2studyonsafetypkpdandpreliminaryefficacyoftheselectivesykinhibitorlanraplenibincombinationwiththeflt3inhibitorgilteritinibinflt3mutatedrraml AT morrislawrencee pb1889kblanra1001aphase1b2studyonsafetypkpdandpreliminaryefficacyoftheselectivesykinhibitorlanraplenibincombinationwiththeflt3inhibitorgilteritinibinflt3mutatedrraml AT carvajalluisa pb1889kblanra1001aphase1b2studyonsafetypkpdandpreliminaryefficacyoftheselectivesykinhibitorlanraplenibincombinationwiththeflt3inhibitorgilteritinibinflt3mutatedrraml AT braygordon pb1889kblanra1001aphase1b2studyonsafetypkpdandpreliminaryefficacyoftheselectivesykinhibitorlanraplenibincombinationwiththeflt3inhibitorgilteritinibinflt3mutatedrraml AT olekelizabetha pb1889kblanra1001aphase1b2studyonsafetypkpdandpreliminaryefficacyoftheselectivesykinhibitorlanraplenibincombinationwiththeflt3inhibitorgilteritinibinflt3mutatedrraml AT cutlerrichard pb1889kblanra1001aphase1b2studyonsafetypkpdandpreliminaryefficacyoftheselectivesykinhibitorlanraplenibincombinationwiththeflt3inhibitorgilteritinibinflt3mutatedrraml AT dimartinojorge pb1889kblanra1001aphase1b2studyonsafetypkpdandpreliminaryefficacyoftheselectivesykinhibitorlanraplenibincombinationwiththeflt3inhibitorgilteritinibinflt3mutatedrraml AT steineytan pb1889kblanra1001aphase1b2studyonsafetypkpdandpreliminaryefficacyoftheselectivesykinhibitorlanraplenibincombinationwiththeflt3inhibitorgilteritinibinflt3mutatedrraml |